Logo image of JSPR

JASPER THERAPEUTICS INC (JSPR) Stock Fundamental Analysis

NASDAQ:JSPR - Nasdaq - US4718712023 - Common Stock - Currency: USD

5.15  -0.11 (-2.09%)

After market: 5.15 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to JSPR. JSPR was compared to 557 industry peers in the Biotechnology industry. JSPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. JSPR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JSPR has reported negative net income.
In the past year JSPR has reported a negative cash flow from operations.
JSPR had negative earnings in each of the past 5 years.
JSPR had a negative operating cash flow in each of the past 5 years.
JSPR Yearly Net Income VS EBIT VS OCF VS FCFJSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

JSPR has a Return On Assets of -136.78%. This is amonst the worse of the industry: JSPR underperforms 84.02% of its industry peers.
JSPR has a worse Return On Equity (-186.49%) than 66.79% of its industry peers.
Industry RankSector Rank
ROA -136.78%
ROE -186.49%
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-80.67%
ROE(3y)-100.82%
ROE(5y)-142.02%
ROIC(3y)N/A
ROIC(5y)N/A
JSPR Yearly ROA, ROE, ROICJSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JSPR Yearly Profit, Operating, Gross MarginsJSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, JSPR has more shares outstanding
Compared to 5 years ago, JSPR has more shares outstanding
There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JSPR Yearly Shares OutstandingJSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
JSPR Yearly Total Debt VS Total AssetsJSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -7.25, we must say that JSPR is in the distress zone and has some risk of bankruptcy.
JSPR's Altman-Z score of -7.25 is on the low side compared to the rest of the industry. JSPR is outperformed by 68.40% of its industry peers.
JSPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.25
ROIC/WACCN/A
WACCN/A
JSPR Yearly LT Debt VS Equity VS FCFJSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 4.31 indicates that JSPR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.31, JSPR is in line with its industry, outperforming 47.94% of the companies in the same industry.
JSPR has a Quick Ratio of 4.31. This indicates that JSPR is financially healthy and has no problem in meeting its short term obligations.
JSPR has a Quick ratio (4.31) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.31
Quick Ratio 4.31
JSPR Yearly Current Assets VS Current LiabilitesJSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.93% over the past year.
EPS 1Y (TTM)6.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

JSPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.93%
EPS Next 2Y-5.13%
EPS Next 3Y-7.85%
EPS Next 5Y9.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JSPR Yearly Revenue VS EstimatesJSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
JSPR Yearly EPS VS EstimatesJSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JSPR. In the last year negative earnings were reported.
Also next year JSPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JSPR Price Earnings VS Forward Price EarningsJSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JSPR Per share dataJSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as JSPR's earnings are expected to decrease with -7.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.13%
EPS Next 3Y-7.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JSPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JASPER THERAPEUTICS INC

NASDAQ:JSPR (6/20/2025, 8:00:02 PM)

After market: 5.15 0 (0%)

5.15

-0.11 (-2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners88.04%
Inst Owner Change-13.87%
Ins Owners1.27%
Ins Owner Change0%
Market Cap77.35M
Analysts84.71
Price Target48.83 (848.16%)
Short Float %11.64%
Short Ratio8.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.2%
Min EPS beat(2)-29.09%
Max EPS beat(2)-5.32%
EPS beat(4)1
Avg EPS beat(4)-8.8%
Min EPS beat(4)-29.09%
Max EPS beat(4)12.67%
EPS beat(8)4
Avg EPS beat(8)-0.99%
EPS beat(12)8
Avg EPS beat(12)1.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.43%
PT rev (3m)-21.37%
EPS NQ rev (1m)0.73%
EPS NQ rev (3m)2.62%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)-16.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.83
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-5.24
EYN/A
EPS(NY)-5.37
Fwd EYN/A
FCF(TTM)-4.68
FCFYN/A
OCF(TTM)-4.64
OCFYN/A
SpS0
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -136.78%
ROE -186.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-80.67%
ROE(3y)-100.82%
ROE(5y)-142.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.31
Quick Ratio 4.31
Altman-Z -7.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)41.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.89%
EPS Next Y-9.93%
EPS Next 2Y-5.13%
EPS Next 3Y-7.85%
EPS Next 5Y9.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.33%
EBIT Next 3Y-22.35%
EBIT Next 5YN/A
FCF growth 1Y-65.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.05%
OCF growth 3YN/A
OCF growth 5YN/A